Protective effects of peroxisome proliferator-activated receptor γ ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury

Transplantation

Volumn 84, Issue 2, 2007, Pages 207-213

  Doi, Shigehiro ^a   Masaki, Takao ^a,b   Arakawa, Tetsuji ^a   Takahashi, Shunsuke ^a   Kawai, Toru ^a   Nakashima, Ayumu ^a   Naito, Takayuki ^a   Kohno, Nobuoki ^a   Yorioka, Noriaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Hepatocyte growth factor; Peroxisome proliferator activated receptor gamma; Renal ischemia reperfusion

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CASPASE 3; GROWTH FACTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SINGLE STRANDED DNA; TROGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; ISCHEMIA; KIDNEY ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TEMPERATURE DEPENDENCE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CHROMANS; CREATININE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FAILURE, ACUTE; LIGANDS; MALE; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TREATMENT OUTCOME; UREA; VASODILATOR AGENTS;

EID: 34547629755     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000269614.21367.3f     Document Type: Article

References (45)

1. Nissenson AR. Acute renal failure: Definition and pathogenesis. Kidney Int 1998; 66: S7.
2. Hetzel GR, Klein B, Brause M, et al. Risk factors for delayed graft function after renal transplantation and their significance for log-term clinical outcome. Transpl Int 2002; 15: 10.
3. Dong Z, Saikumar P, Patel Y, et al. Serine protease inhibitors suppress cytochrome c-mediated caspase-9 activation and apoptosis during hypoxia-reoxygenation. Biochem J 2000; 347: 669.
4. Schumer M, Colombel MC, Sawczuk IS, et al. Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. Am J Pathol 1992; 140: 831.
5. Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Cell Biol 1998; 10: 384.
6. Kaplan F, Al-Majali K, Betteridge DJ. PPARs, insulin resistance and type 2 diabetes. J Cardiovas Risk 2001; 8: 211.
7. Imano E, Motomura M, Kanda T, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135.
8. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complication of metabolic syndrome. J Am Soc Nephrol 2004; 15: 2801.
9. Sivarajah A, Chatterjee PK, Patel NSA, et al. Agonists of peroxisomeproliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003; 23: 267.
10. 2 ameliorates ischemic acute renal failure. Cardiovasc Res 2004; 61: 630.
11. Ito K, Shimada J, Kato D, et al. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion injury in rats. Eur J Cardiothor Surg 2004; 25: 530.
12. Villegas I, Martín AR, Toma W, Lasta CA. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: Role of oxygen free radicals generation. Eur J Pharmacol 2004; 505: 195.
13. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440.
14. Igawa T, Matsumoto K, Kanda S, et al. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol Renal Physiol 1993; 265: F61.
15. Fiaschi-Taesch NM, Santos S, Reddy V, et al. Prevention of acute renal failure by targeted delivery of growth factors to the proximal tubule in transgenic mice: The efficacy of parathyroid hormone-related protein and hepatocyte growth factor. J Am Soc Nephrol 2004; 15: 112.
16. Li Y, Wen X, Spataro BC, et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-γ agonists. J Am Soc Nephrol 2006; 17: 54.
17. Jiang JG, Johnson C, Zarnegar R. Peroxisome proliferator-activated receptor γ-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. J Biol Chem 2001; 276: 25049.
18. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: Immunohistochemistry using antibodies to cleaved caspase-3. J Histochem 2002; 50: 449.
19. Naruse I, Keino H, Kawarada Y. Antibody against single-stranded DNA detects both programmed cell death and drug-induced apoptosis. Histochemistry 1994; 101: 73.
20. Masaki T, Foti R, Hill PA, et al. Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. Kidney Int 2003; 63: 1256.
21. Kiribayashi K, Masaki T, Naito T, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int 2005; 67: 1126.
22. Naito T, Masaki T, Nikolic-Paterson DJ, et al. Angiotensin IIinduced thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: A mechanism for activation of latent TGF-β. Am J Physiol Renal Physiol 2004; 286: F278.
23. Hirai T, Masaki T, Kuratsune M, et al. PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation. Clin Exp Immunol 2006; 144: 353.
24. Izumi T, Enomoto S, Hosiyama K, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ter 1996; 277: 1630.
25. Kawai K, Kawasaki-Tokui Y, Odaka T, et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim-Forsch/Drug Res 1997; 47: 356.
26. Collino M, Patel NSA, Lawrence KM, et al. The selective PPARγ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia reperfusion. Kidney Int 2005; 68: 529.
27. Kaushal GP, Singh AB, Shah SV. Identification of gene family of caspases in rat kidney altered expression in ischemia-reperfusion injury. Am J Physiol Renal Physiol 1998; 274: F587.
28. Feldenberg LR, Thevananther S, Del Rio M, et al. Partial ATP depletion induces Fas- and caspase-mediated apoptosis in MCDK cells. Am J Physiol Renal Physiol 1999; 276: F837.
29. Burns AT, Davies DR, Mclaren AJ, et al. Apoptosis in ?schemia/reperfusion injury of human renal allografts. Transplant 1998; 66: 872.
30. Yoshimura R, Matsuyama M, Segawa Y, et al. Study of peroxisome proliferator-activated receptor (PPAR)-γ in renal ischemia-reperfusion injury. Transplant Proc 2004; 36: 1946.
31. Liu KX, Kato Y, Narukawa M, et al. Importance of the liver in the plasma clearance of hepatocyte growth factor in rats. Am J Physiol Gastrointest Liver Physiol 1992; 263: G642.
32. Liu KX, Kato Y, Kato M, et al. Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. Am J Physiol Endocrinol Metab 1997; 273: E891.
33. Matsumoto K, Nakamura T. Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases. Kidney Int 2001; 59: 2023.
34. Liu Y, Tolbert EM, Lin L, et al. Up-regulation of hepatocyte growth factor receptor: An amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int 1999; 55: 442.
35. Ishibashi K, Sasaki S, Sakamoto H, et al. Expression of receptor gene for hepatocyte growth factor in kidney after unilateral nephrectomy and renal injury. Biochem Biophys Res Commun 1992; 187: 1454.
36. Rabkin R, Fervenza F, Tsao T, et al. Hepatocyte growth factor receptor in acute tubular necrosis. J Am Soc Nephrol 2001; 12: 531.
37. Vijayan A, Martin DR, Sadow JL, et al. Hepatocyte growth factor inhibits apoptosis after ischemic renal injury in rats. Am J Kid dis 2001; 38: 274.
38. Funakoshi H, Nakamura T. Hepatocyte growth factor: From diagnosis to clinical applications. Clin Chim Acta 2003; 327: 1.
39. Nakamura T, Mizuno S, Matsumoto K, et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106: 1511.
40. Lauriat S, Linas SL. The role of neutrophils in acute renal failure. Semin Nephrol 1998; 18: 498.
41. Mizuno S, Nakamura T. Prevention of neutrophil extravasation by hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys. Am J Pathol 2005; 166: 1895.
42. Gong R, Rifai A, Dworkin LD. Hepatocyte growth factor suppresses acute renal inflammation by inhibition of endothelial E-selectin. Kidney Int 2006; 69: 1166.
43. Durão MS Jr, Razvickas CV, Gonçalves EAP, et al. The role of growth factors on renal tubular cells submitted to hypoxia and deprived of glucose. Ren Fail 2003; 25: 341.
44. Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am J Physiol Renal Physiol 1999; 277: F624.
45. Bardelli A, Longati P, Albero D, et al. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996; 15: 6205.